Search...
/
The Fly Cast
Press play to listen
Competitive Advantages
Risks
Competitive Advantages
Proprietary RTGel Delivery System: Urogen's innovative RTGel reverse-thermal hydrogel allows for sustained, local drug exposure in the urinary tract, a unique platform that enhances efficacy and reduces systemic side effects.
Approved Novel Uro-Oncology Therapies: The company has successfully developed and gained approval for Jelmyto® (for LG UTUC) and UGN-102 (Urothel™ for LG IR NMIBC), addressing critical unmet needs with non-surgical options.
Focus on High Unmet Needs Markets: Urogen targets rare and difficult-to-treat urological cancers where existing treatment options are limited, leading to less competition and higher market acceptance for novel therapies.
Risks
Clinical Trial Success for UGN-102: The successful completion and positive outcomes of pivotal clinical trials for UGN-102 are critical for its potential regulatory approval and future commercialization. Failure to meet endpoints or unexpected safety issues would significantly harm the company's prospects.
Regulatory Approval for UGN-102: Even with successful clinical trials, obtaining regulatory approval from agencies like the FDA for UGN-102 is not guaranteed and involves a complex, lengthy process that could be subject to delays or denial.
Commercialization of Jelmyto: The continued commercial success and market adoption of Jelmyto for low-grade upper tract urothelial carcinoma faces challenges including physician awareness, patient access, reimbursement complexities, and competition.
Today
5:14 PM
5:08 PM
Over a week ago
Jul 8, 8:03 AM
May 15, 8:30 AM
May 13, 9:15 AM
May 11, 8:27 AM
May 11, 6:11 AM
May 7, 7:40 AM
May 6, 9:49 AM
Apr 9, 4:21 PM
Mar 30, 9:00 AM
Mar 13, 8:12 AM
Mar 2, 8:04 AM
Mar 2, 8:03 AM
Mar 2, 7:56 AM
Feb 27, 8:37 AM
Jan 5, 8:28 AM
Dec 5, 8:09 AM
Nov 6, 4:27 PM
Nov 6, 8:02 AM
Nov 6, 8:01 AM
Oct 27, 8:14 AM
Oct 2, 8:05 AM
